General Information of Drug (ID: DM5GQD7)

Drug Name
Metoprine Drug Info
Synonyms
METOPRINE; Methodichlorophen; DDMP; 7761-45-7; Metoprine [USAN]; BW-197U; TCMDC-123931; NSC-19494; SK 5265; 5-(3,4-DICHLOROPHENYL)-6-METHYLPYRIMIDINE-2,4-DIAMINE; U 197; NSC7364; U-197; UNII-2L9RKX796Q; Metoprine (USAN); BW 50-197; METOPRINE, METHODICHLOROPHEN; 5-(3,4-Dichlorophenyl)-6-methyl-2,4-pyrimidinediamine; NSC 7364; 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl-; NSC 19494; BW50197; BRN 0223622; 5-(3,4-Dichlorphenyl)-6-methyl-2,4-pyrimidindiamin; 2,4-Diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine; MLS002701892; DDMP; BW 197 U; BW 1970; BW 197U; BW 50197; BW 50,197; 2,4-Diamino-5-(3',4'-dichlorophenyl)-6-methyl pyrimidine; Chloroaniline 1
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Phase 2 [1] , [2]
Cross-matching ID
PubChem CID
24466
CAS Number
CAS 7761-45-7
TTD Drug ID
DM5GQD7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diphenhydramine DMKQTBA Meniere disease AB31.0 Approved [3]
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [5]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [6]
4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE DM68S9F Discovery agent N.A. Investigative [3]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Proguanil DMBL79I Malaria 1F40-1F45 Approved [7]
Meprobamate DMHM93Y Anxiety disorder 6B00-6B0Z Approved [8]
Pralatrexate DMAO80I Breast cancer 2C60-2C65 Approved [9]
Ustekinumab DMHTYK3 Plaque psoriasis EA90.0 Approved [10]
Trimetrexate DMDEA85 Toxoplasmosis 1F57 Approved [11]
MCB-3837 DM0R4Z5 Malaria 1F40-1F45 Approved [8]
Chlorproguanil DM1IFGT Malaria 1F40-1F45 Approved [8]
LY333531 DMGMC8H Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
Aminopterin DMQ9RBV leukaemia 2A60-2B33 Withdrawn from market [13]
2-Sulfhydryl-Ethanol DMJBO3D Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine N-methyltransferase (HNMT) TT2B6EV HNMT_HUMAN Inhibitor [3]
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7412).
2 ClinicalTrials.gov (NCT01579110) Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.. U.S. National Institutes of Health.
3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
5 Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
8 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
9 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
10 Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
11 Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
12 Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
13 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.